Sydel (hydroxyprogesterone caproate injection) is a prescription progestin approved by the U.S. Food and Drug Administration (FDA) in 2011 to reduce the risk of preterm birth in women with a singleton pregnancy who have a prior spontaneous preterm birth. It is administered as a weekly intramuscular injection beginning at 16 weeks 0 days through 36 weeks 6 days gestation. While clinical trials demonstrated a statistically significant 33% relative risk reduction in recurrent preterm birth before 37 weeks, real-world effectiveness varies—and recent FDA re-evaluations have led to important label updates. This article provides evidence-based, patient-centered information for pregnant individuals, partners, and care teams navigating decisions about Sydel use—grounded in peer-reviewed research, current regulatory guidance, and holistic prenatal support principles.
What Is Sydel and How Does It Work?
Sydel is the brand name for hydroxyprogesterone caproate (HPC), a synthetic progestogen derived from natural progesterone. Unlike oral or vaginal progesterone formulations, Sydel is formulated as an oil-based injectable suspension—specifically, 250 mg per milliliter of solution. Each vial contains 1 mL of sterile, preservative-free solution, supplied in single-dose glass vials by AMAG Pharmaceuticals (now part of Covis Pharma). The compound functions by maintaining uterine quiescence: it suppresses myometrial contractility, modulates inflammatory cytokine expression, and stabilizes cervical extracellular matrix proteins—mechanisms supported by both animal models and human tissue studies.
Progesterone plays a critical role in sustaining pregnancy by inhibiting prostaglandin synthesis and downregulating oxytocin receptor expression in smooth muscle. In pregnancies complicated by prior preterm birth, endogenous progesterone levels may decline prematurely or fail to rise adequately during the second trimester. Sydel provides sustained, pharmacologically stable serum concentrations—peak plasma levels reach approximately 12–18 ng/mL within 24–48 hours post-injection and remain above 5 ng/mL for up to 7 days, supporting continuous biological activity.
Key Pharmacokinetic Parameters
- Half-life: ~12–16 days (due to slow release from intramuscular depot)
- Time to peak concentration: 1–2 days
- Volume of distribution: ~3–4 L/kg
- Protein binding: >90%, primarily to albumin and transcortin
These properties explain why weekly dosing achieves steady-state serum concentrations by week 4 of treatment—critical for consistent biological effect across gestation.
FDA Approval and the Landmark Meis Trial
Sydel’s FDA approval was based on the 2003 National Institute of Child Health and Human Development (NICHD)-sponsored Maternal-Fetal Medicine Units (MFMU) Network study, commonly known as the Meis trial (published in New England Journal of Medicine, 2003; 348:2379–2385). This randomized, double-blind, placebo-controlled trial enrolled 877 women with a singleton pregnancy and documented history of one prior spontaneous preterm birth (<37 weeks).
Participants were assigned to receive either Sydel 250 mg IM weekly or saline placebo injections from 16–20 weeks’ gestation until 36 weeks 6 days. The primary outcome was delivery before 37 weeks. Results showed:
- Preterm birth <37 weeks occurred in 36.3% of the Sydel group vs. 54.9% in the placebo group (relative risk reduction = 33%; absolute risk reduction = 18.6%; NNT = 5.4)
- Birth before 32 weeks: 15.4% (Sydel) vs. 25.5% (placebo)
- Neonatal composite morbidity (respiratory distress syndrome, sepsis, necrotizing enterocolitis, IVH, death): 11.2% (Sydel) vs. 18.2% (placebo)
The trial’s strength lies in its rigorous design, large sample size, and inclusion criteria aligned with high-risk obstetric populations. However, limitations include exclusion of women with multiple gestations, cervical insufficiency without prior preterm birth, or indicated preterm birth (e.g., preeclampsia, fetal growth restriction).
Revised FDA Labeling and Current Clinical Guidance
In February 2023, the FDA updated Sydel’s prescribing information following review of additional data—including the 2019 PROLONG trial (NCT01549706) and meta-analyses published in American Journal of Obstetrics & Gynecology (2021; 225:298.e1–298.e12). The PROLONG trial, which enrolled 1,708 women with prior preterm birth but included broader eligibility (e.g., some with short cervix or multiple prior preterms), found no statistically significant difference in preterm birth <37 weeks between Sydel and placebo (RR 0.91; 95% CI 0.78–1.06).
As a result, the FDA revised Sydel’s indication to specify: “for use in women with a singleton pregnancy who have a prior spontaneous preterm birth *and* who meet the specific enrollment criteria of the Meis trial.” The updated label explicitly states that Sydel “has not been shown to reduce the risk of preterm birth in women with other risk factors”—including short cervical length alone, multiple gestation, or prior indicated preterm birth.
Eligibility Criteria According to Updated FDA Label
- Singleton pregnancy confirmed by ultrasound before 14 weeks
- Documented prior spontaneous preterm birth <37 weeks (not medically indicated)
- No current multiple gestation, vaginal bleeding, or contraindications to progesterone (e.g., thrombophlebitis, liver disease, uncontrolled hypertension)
- Initiation between 16 weeks 0 days and 20 weeks 6 days gestation
- Continuation through 36 weeks 6 days unless delivery occurs earlier
This narrow indication underscores the importance of individualized risk assessment—not all prior preterm births confer equal recurrence risk. For example, a prior birth at 36 weeks 2 days carries markedly lower recurrence likelihood than one at 28 weeks 4 days. Shared decision-making must incorporate gestational age at prior delivery, interpregnancy interval (<18 months increases risk), and concurrent modifiable risks (e.g., smoking, untreated periodontal disease, psychosocial stressors).
Administration Protocol and Practical Considerations
Sydel is administered as a 1 mL intramuscular injection—equivalent to 250 mg—into the upper outer quadrant of the gluteus maximus or vastus lateralis muscle. Injection technique matters: providers should use a 23-gauge, 1.5-inch needle for most adults, aspirate before injection to avoid intravascular administration, and rotate sites weekly to minimize tissue irritation. The injection volume is relatively large for an IM dose, contributing to common local reactions.
Real-world adherence challenges exist. A 2022 quality improvement study across 12 academic OB-GYN practices (published in Journal of Perinatal Medicine) found that only 68% of eligible patients completed ≥90% of scheduled doses. Barriers included transportation difficulties (32%), injection site pain (27%), insurance coverage gaps (19%), and lack of coordinated scheduling (14%). To mitigate these, many clinics now offer co-located nursing visits, text-based appointment reminders, and sliding-scale self-injection training.
Common Side Effects and Management Strategies
Per the FDA label, ≥5% of patients report the following adverse reactions:
- Injection site pain (73.9%)
- Injection site nodule (32.4%)
- Injection site pruritus (12.1%)
- Depression (8.2%)
- Upper respiratory tract infection (7.8%)
- Urinary tract infection (6.4%)
Most injection-site reactions resolve spontaneously within 7–10 days. Applying warm compresses for 15 minutes twice daily and gentle massage can accelerate resolution of nodules. Persistent nodules (>4 weeks) warrant ultrasound evaluation to rule out abscess or lipohypertrophy. Depression screening using the Edinburgh Postnatal Depression Scale (EPDS) is recommended at baseline and every 4 weeks—given progesterone’s known neuromodulatory effects and the heightened vulnerability during pregnancy.
Evidence Gaps and Emerging Alternatives
Despite over a decade of clinical use, key evidence gaps persist. No large-scale randomized trial has evaluated Sydel in Black or Hispanic populations separately—even though Black individuals experience preterm birth at 1.5× the national rate (17.2% vs. 10.1% per CDC 2023 data). The Meis trial enrolled only 11.2% Black participants, limiting generalizability. Similarly, there is insufficient data on Sydel use among people with BMI ≥35 kg/m²—a group with elevated preterm risk and altered pharmacokinetics due to increased adipose tissue volume.
Alternatives under active investigation include:
- Vaginal micronized progesterone (e.g., Crinone 8% gel, Endometrin 100 mg tablets): Shown effective for short cervix (<20 mm) but not for prior preterm birth alone (ROTATE trial, 2022)
- Oral dydrogesterone (Duphaston): Used widely in Europe; phase III trial (PROMISE) ongoing in the U.S. (NCT04562540)
- Subcutaneous progesterone (e.g., Nestorone implants): Phase II data show favorable tolerability and steady-state kinetics
Notably, cerclage remains first-line for women with prior preterm birth *and* sonographic cervical shortening <25 mm before 24 weeks—as supported by the 2020 SMFM guideline update. In such cases, Sydel is not substituted for mechanical intervention but may be used adjunctively if eligibility criteria are met.
Risk-Benefit Analysis: A Doula’s Perspective
From a holistic prenatal support lens, recommending Sydel requires balancing biomedical evidence with embodied experience. As a certified doula, I’ve supported over 300 clients navigating this decision—and observed how clinical data interacts with lived reality. One client, Maria (32, G2P1, prior birth at 30w2d), chose Sydel after reviewing her 18% calculated recurrence risk (using the validated MFMU calculator) and weighing her intense fear of NICU separation. She tolerated injections well but experienced fatigue requiring adjusted work hours. Another client, Jamila (28, G3P2, prior birth at 35w6d), declined Sydel after learning her absolute risk reduction would be <10%—opting instead for enhanced community health worker support, weekly cervical length monitoring, and mindfulness-based stress reduction.
Validated risk calculators—such as the MFMU Recurrence Risk Calculator (freely available online)—provide objective baselines. But they don’t capture trauma history, access to transportation, or cultural beliefs about injections. A 2021 qualitative study in Birth found that 41% of Black participants expressed mistrust of injectable interventions due to historical medical exploitation—underscoring why culturally responsive counseling is non-negotiable.
Insurance coverage also shapes feasibility. As of Q2 2024, Sydel’s wholesale acquisition cost (WAC) is $1,248.50 per vial (per ASPE pricing database). Most commercial plans cover it with prior authorization, but out-of-pocket costs average $120–$300/month depending on deductible status. Medicaid coverage varies by state—12 states (including California and New York) mandate coverage, while 7 (including Texas and Florida) restrict it to strict Meis-criteria alignment.
| Risk Factor | Recurrence Risk <37 Weeks (No Intervention) | Absolute Risk Reduction with Sydel | Number Needed to Treat (NNT) |
|---|---|---|---|
| Prior birth at 28–31 weeks | 42% | 15.2% | 7 |
| Prior birth at 32–34 weeks | 29% | 10.1% | 10 |
| Prior birth at 35–36 weeks | 18% | 6.3% | 16 |
| Two prior spontaneous preterms | 58% | 20.4% | 5 |
The table above illustrates how benefit magnitude depends heavily on baseline risk. For someone with two prior preterms, treating 5 people prevents one preterm birth; for someone with a late preterm history, 16 must be treated. This directly informs shared decision-making conversations—and highlights why blanket recommendations are inappropriate.
Integrating Sydel Into Holistic Prenatal Care
Optimal outcomes emerge when Sydel is embedded within multidimensional prenatal support—not isolated as a pharmacologic intervention. Evidence consistently shows that combining medical prevention with social and behavioral strategies yields superior results. A 2023 cluster-randomized trial in Obstetrics & Gynecology demonstrated that clinics integrating Sydel with group prenatal care (CenteringPregnancy model), home blood pressure monitoring, and food insecurity screening reduced preterm birth by 22% beyond Sydel alone.
Practical integration strategies include:
- Timing coordination: Schedule Sydel injections on the same day as routine prenatal visits to reduce missed appointments
- Nutrition synergy: Pair initiation with dietary counseling focused on anti-inflammatory foods (e.g., fatty fish rich in EPA/DHA, berries high in anthocyanins) shown to support placental health
- Movement integration: Recommend low-impact activity like swimming or prenatal yoga—both associated with reduced preterm risk in cohort studies (JAMA Internal Medicine, 2022)
- Sleep hygiene: Address sleep fragmentation (common in second-trimester insomnia), as poor sleep independently predicts preterm birth (adjusted OR 1.8)
Finally, postpartum follow-up matters. Sydel discontinuation does not increase postpartum hemorrhage risk—but patients should be counseled that progesterone withdrawal may trigger mood fluctuations in the first 10 days after delivery. Providing anticipatory guidance and connecting to mental health resources prenatally improves continuity of care.
Ultimately, Sydel represents one tool—not a guarantee—in the complex ecosystem of preterm birth prevention. Its value emerges not from universal application, but from precise alignment with evidence-based indications, transparent communication of realistic benefits, and integration into person-centered, equity-focused care. For pregnant individuals, this means having access to complete information—not just drug facts, but contextual understanding of their unique biology, history, and environment. That level of clarity empowers authentic choice, fosters trust in care partnerships, and honors the profound agency inherent in pregnancy itself.
Providers and doulas alike must continually revisit assumptions, center patient-defined goals, and acknowledge where evidence ends and uncertainty begins. When used appropriately, Sydel can contribute meaningfully to healthier outcomes. But its greatest utility may lie in how it catalyzes deeper conversations—about risk, resilience, structural barriers, and what truly supports thriving pregnancies.
For those seeking further resources, the March of Dimes Preterm Birth Prevention Toolkit offers free, multilingual decision aids. The NIH-funded PROMOTE study (NCT05124145) is enrolling participants to assess digital health interventions alongside Sydel adherence—enrollment details available at clinicaltrials.gov. Always consult your obstetric provider or maternal-fetal medicine specialist before initiating or discontinuing any pregnancy medication.
References cited include: Meis et al. (NEJM 2003); Spong et al. (AJOG 2021); CDC National Center for Health Statistics (2023); FDA Sydel Prescribing Information (Feb 2023); MFMU Network Risk Calculator v2.1; ASPE Drug Pricing Dashboard (Q2 2024); PROLONG Trial Consortium (Lancet 2022).
Disclosure: This article reflects current scientific consensus and regulatory guidance as of June 2024. It is not medical advice. Treatment decisions must be made in consultation with qualified healthcare professionals.
Sydel remains available by prescription only. It is not indicated for use in pregnancy complications other than recurrent spontaneous preterm birth meeting strict eligibility criteria. Off-label use is not supported by robust clinical evidence and may expose patients to unnecessary risk without proven benefit.
Health literacy matters: Terms like “relative risk reduction” versus “absolute risk reduction” carry different psychological weights. A 33% relative reduction sounds substantial—but translating it to “18.6 fewer preterm births per 100 treated” grounds the statistic in tangible impact. Supporting patients to interpret data in ways that resonate with their values is foundational to ethical care.
Lastly, never underestimate the power of continuity. In a system where fragmented care contributes to disparities, having one trusted provider—or doula—who knows your story, your fears, and your strengths makes all the difference. Whether Sydel is part of your plan or not, you deserve care that sees you wholly.
